Exploring blood-based biomarkers in late-life depression: Correlates of psychotherapeutic treatment outcomes.

ABSTRACT:

Background

Major depressive disorder is a prevalent and debilitating mental health condition contributing to a growing global burden. Late-life depression (LLD), affecting individuals over 60 years of age, is further associated with elevated risks for cardiovascular diseases, cognitive decline, and dementia. Treatment responses vary widely, potentially due to underlying neurodegeneration and cellular senescence. We aimed to explore blood-based biomarkers related to Alzheimer's disease and senescence-associated secretory phenotype (SASP) proteins, seeking to identify biological underpinnings of LLD and their association with response to psychotherapy.

Methods

We performed a secondary analysis of the Cognitive Behavioral Therapy for Late-Life Depression (CBTlate) trial in 228

SUBMITTER: Martino-Adami PV 

PROVIDER: S-EPMC12925672 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature